CAS: 1047634-65-0; (S)-N-(1-Amino-3-(3,4-Difluorophenyl)Propan-2-yl)-5-Chloro-4-(4-Chloro-1-Methyl-1H-Pyrazol-5-yl)Furan-2-Carboxamide
该化合物是针对AKT(Portein kinase B)的强大和选择性的小型分子抑制器,是PI3K/AKT/mtor信号传输路径的一个关键组成部分.这条路径经常在各种癌症中出现畸变,使AKT成为具有吸引力的治疗目标. Uprosertib对AKT的外形具有高度的特性,抑制了它们的磷酸化和下游信号,从而抑制了肿瘤细胞的扩散和生存.其特征精良的药理动力学特征和临床前方模型中显示的活动凸显了其作为调查肿瘤治疗治疗的潜在作用.该化合物对AKT依赖的路径进行调节并产生最小非目标效果的能力强调了其在PI3K/AKT/Mtor路径启动的恶性研究与临床发展中的实用性.
- 英文名称(S)-N-(1-Amino-3-(3,4-Difluorophenyl)Propan-2-yl)-5-Chloro-4-(4-Chloro-1-Methyl-1H-Pyrazol-5-yl)Furan-2-Carboxamide
- 中文名称Uprosertib,GSK2141795抑制剂
- IUPAC名称(S)-N-(1-amino-3-(3,4-difluorophenyl)propan-2-yl)-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)furan-2-carboxamide
- CAS编号1047634-65-0
- MFCD编号:MFCD28144686
- EINECS号:629-867-9
- FDA UNII编号:ZXM835LQ5E
- 分子式:C18H16Cl2F2N4O2分子量:429.25
- 产品CID: 86390
- 同类组份化合物CAS1047635-80-2 (HCl)1047634-65-0 (free base)
- 产品分类生物化工 → 生化试剂 → 激动剂抑制剂
物理性质
- 密度1.52±0.1 g/cm3 (20 ºC 760 Torr),
- PSA:86.08
- LogP:4.6561
- 溶解性DMSO:45.33(Max Conc. mg/mL);105.6(Max Conc. Mm) DMF:1.0(Max Conc. mg/mL);2.33(Max Conc. Mm) Ethanol:85.0(Max Conc. mg/mL);198.02(Max Conc. Mm)
- 外观形态白色至类白色粉末
- 储存条件储存在 -20°C
- 产品应用该化合物是具有IC50值分别为180纳米,328纳米和38纳米的强力选择性,AKT1,AKT2和AKT3的ATP-AKTT抑制剂;它处于第二阶段临床调查阶段;它禁止BT474和LNCAP细胞中多种AKTE亚基质的磷酸酯磷酸盐;它优于抑制肿瘤细胞扩散,并使用活性AK T信号,诱使LNCPP,BT 474,A3和I9.2细胞线的细胞循环停止,并在SKOV3和PEO4细胞中加强脊髓灰素诱发的骨硬化,同时导致生长阻塞;在VIVIVIVO,它达到BT-4744乳腺癌的肿瘤生长抑制61%,在100毫克/千克(P.O.)和SKO V3卵巢癌的肿瘤抑制剂中61%的肿瘤增长抑制剂,在30毫克/公斤(PO.).
MSDS等安全信息
欧盟法规
ECHA物质C&L通报合成工艺路线路线简述
📜2-Furancarboxamide,5-Chloro-4-(4-Chloro-1-Methyl-1H-Pyrazol-5-yl)-N-[(1S)-1-[(3,4-Difluorophenyl)Methyl]-2-(1,3-Dihydro-1,3-Dioxo-2H-Isoindol-2-yl)Ethyl]-反应生成Uprosertib,Gsk2141795抑制剂
参考文献:Inhibitors Of Akt Activity
标题:Inhibitors Of Akt Activity
摘要:本发明涉及一种新型杂环羧酰胺化合物,其作为蛋白激酶b活性的抑制剂以及在癌症和关节炎治疗中的应用.
专利信息
专利号:US-12391691-B2
优先权日:2018-11-16
标题:Synthesis of key intermediate of KRAS G12C inhibitor compound
发明人：PARSONS ANDREW THOMAS; COCHRAN BRIAN MCNEIL; POWAZINIK IV WILLIAM; CAPORINI MARC ANTHONY
权利人:AMGEN INC
摘要:The present invention relates to an improved, efficient, scalable process to prepare intermediate compounds, such as compound 5M, having the structure n nuseful for the synthesis of compounds that target KRAS G12C mutations, such as
专利号:US-2025206736-A1
优先权日:2019-11-14
标题 :Synthesis of kras g12c inhibitor compound
发明人：CORBETT MICHAEL THOMAS; CAILLE SEBASTIEN
权利人:AMGEN INC
摘要:The present disclosure relates to an improved, efficient, scalable process to prepare intermediate compounds, such as 2-isopropyl-4-methylpyridin-3-amine, useful for the synthesis of compounds, such as Compound 9, for the treatment of KRAS G12C mutated cancers.
专利号:US-2023192681-A1
优先权日:2019-11-14
标 题 :Improved synthesis of kras g12c inhibitor compound
专利号:US-11299491-B2
优先权日:2018-11-16
标 题:Synthesis of key intermediate of KRAS G12C inhibitor compound
专利号:US-2025206735-A1
优先权日:2018-11-16
标题:Synthesis of key intermediate of kras g12c inhibitor compound
专利号:US-12391689-B2
优先权日:2018-11-16
标题 :Synthesis of key intermediate of KRAS G12C inhibitor compound
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: Dumble M, Crouthamel MC, Zhang SY, Schaber M, Levy D, Robell K, Liu Q, Figueroa DJ, Minthorn EA, Seefeld MA, Rouse MB, Rabindran SK, Heerding DA, Kumar R. Discovery of Novel AKT Inhibitors with Enhanced Anti-Tumor Effects in Combination with the MEK Inhibitor. PLoS One. 2014 Jun 30;9(6):e100880. doi: 10.1371/journal.pone.0100880. eCollection 2014.
2: Pachl F, Plattner P, Ruprecht B, Médard G, Sewald N, Kuster B. Characterization of a chemical affinity probe targeting Akt kinases. J Proteome Res. 2013 Aug 2;12(8):3792-800. doi: 10.1021/pr400455j. Epub 2013 Jul 3. doi: 10.1517/13543784.2010.520701. Epub 2010 Sep 16. Review.
合成参考文献
参考文献:10.18632/oncotarget.6153
摘要:Cheraghchi-Bashi A, Parker CA, Curry E, Salazar J, Gungor H, Saleem A, Cunnea P, Rama N, Salinas C, Mills GB, Morris SR, Kumar R, Gabra H, Stronach EA. A putative biomarker signature for clinically effective AKT inhibition: correlation of in vitro, in vivo and clinical data identifies the importance of modulation of the mTORC1 pathway. Oncotarget. 2015 Oct 19;6(39):41736–49. doi: 10.18632/oncotarget.6153.
摘要:S55 | ZINC15PHARMA | Pharmaceuticals from ZINC15 | DOI:10.5281/zenodo.3247749
📝 需求与反馈
尽可能描述清楚需求与问题信息
